US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

SAB Biotherapeutics, Inc. Warrant

0.0341

-0.0028-7.59%

Volume:7.38K

Turnover:207.07

Market Cap:355.02K

PE:-0.01

High:0.0342

Open:0.0301

Low:0.0261

Close:0.0369

52wk High:0.1800

52wk Low:0.0205

Shares:10.41M

Float Shares:10.41M

Volume Ratio:4.03

T/O Rate:0.07%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.8053

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Company Profile

Company Name:

SAB Biotherapeutics, Inc. Warrant

Exchange:

NASDAQ

Establishment Date:

- -

Employees:

- -

Office Location:

- -

Website:

http://www.sabbiotherapeutics.com

Zip Code:

- -

Phone:

- -

Fax:

- -

Introduction:

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development for the treatment or prevention of severe influenza. Further, the company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Sioux Falls, South Dakota.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SABSW/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"SABSW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SABSW\",,,,,undefined,":{"symbol":"SABSW","market":"US","secType":"STK","nameCN":"SAB Biotherapeutics, Inc. Warrant","latestPrice":0.0341,"timestamp":1771621200000,"preClose":0.0369,"halted":0,"volume":7378,"delay":0,"changeRate":-0.07588075880758817,"floatShares":10411067,"shares":10411067,"eps":-2.8053,"marketStatus":"Post-Mkt","change":-0.0028,"latestTime":"02-20 18:52:13 EST","open":0.030101,"high":0.0342,"low":0.0261,"amount":207.0724,"amplitude":0.219512,"askPrice":0.05,"askSize":10000,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-2.8053,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1771635600000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":0.0369,"volumeRatio":4.029932},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SABSW\",,,,,undefined,":{"symbol":"SABSW","floatShares":10411067,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":4.029932,"shares":10411067,"dividePrice":0,"high":0.0342,"amplitude":0.219512,"preClose":0.0369,"low":0.0261,"week52Low":0.0205,"pbRate":"--","week52High":0.18,"institutionHeld":0,"latestPrice":0.0341,"committee":-1,"eps":-2.8053,"divideRate":0,"volume":7378,"delay":0,"ttmEps":-2.8053,"open":0.030101,"prevYearClose":0.0312,"prevWeekClose":0.0373,"prevMonthClose":0.038,"prevQuarterClose":0.0312,"fiveDayClose":0.0373,"twentyDayClose":0.04,"sixtyDayClose":0.0297},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SABSW\",params:#limit:5,,,undefined,":[{"market":"US","date":"2022-08-10","symbol":"SABSW","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1660104000000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2022-03-29","symbol":"SABSW","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1648526400000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SABSW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SABSW\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.sabbiotherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0107},{"period":"1month","weight":0.23},{"period":"3month","weight":0.2424},{"period":"6month","weight":0.3359},{"period":"1year","weight":0.1495},{"period":"ytd","weight":0.1827}],"compareEarnings":[{"period":"1week","weight":0.0047},{"period":"1month","weight":0.0102},{"period":"3month","weight":0.0386},{"period":"6month","weight":0.0607},{"period":"1year","weight":0.1167},{"period":"ytd","weight":0.0038}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development for the treatment or prevention of severe influenza. Further, the company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Sioux Falls, South Dakota.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.116105},{"month":2,"riseRate":0.2,"avgChangeRate":-0.046324},{"month":3,"riseRate":0.2,"avgChangeRate":-0.216922},{"month":4,"riseRate":0.6,"avgChangeRate":0.19006},{"month":5,"riseRate":0.4,"avgChangeRate":0.047835},{"month":6,"riseRate":0.8,"avgChangeRate":0.241663},{"month":7,"riseRate":0.2,"avgChangeRate":-0.12691},{"month":8,"riseRate":0,"avgChangeRate":-0.287815},{"month":9,"riseRate":0.4,"avgChangeRate":0.153879},{"month":10,"riseRate":0.8,"avgChangeRate":0.331354},{"month":11,"riseRate":0.6,"avgChangeRate":0.193674},{"month":12,"riseRate":0.4,"avgChangeRate":-0.159523}],"exchange":"NASDAQ","name":"SAB Biotherapeutics, Inc. Warrant","nameEN":"SAB Biotherapeutics, Inc. Warrant"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"SABSW\",market:\"US\",,,undefined,":null}}